Lenz Therapeutics, Inc. (LENZ)
NASDAQ:LENZ
Earnings Data
Report Date
May 13, 2026After Close (Confirmed)
Period Ending
2026 (Q1)Consensus EPS Forecast
-1.01Last Year’s EPS
-0.53Same Quarter Last Year
Strong Buy
Based on 5 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call presents a cautiously optimistic outlook: product efficacy and early real-world persistence plus strong physician awareness, encouraging prescriber productivity, expanding field coverage, and a robust cash balance are clear positives. However, the launch is capital-intensive with substantial SG&A increases and meaningful Q4 net loss, early-stage NRx growth due to deliberate sampling strategy and category education, limited short-term visibility on refill/conversion metrics, and a relatively low expected direct product gross margin. Management’s tone is constructive and execution-focused, positioning the company to scale adoption over the coming quarters while they absorb near-term investment-driven losses.Company Guidance
Product Efficacy Demonstrated in Real World
LENZ reports the product 'clearly works' with many patients noticing effects within ~30 minutes and near-vision benefits lasting throughout the workday; early patient persistence and refill behavior are described as encouraging.
Early Commercial Traction — Units and Prescribers
From launch through the end of the period the company expects to have sold over 45,000 monthly packs/boxes and to have more than 10,000 prescribing eye care professionals (ECPs); Q4 reported net product revenues of approximately $1.6M and over 20,000 monthly paid and filled prescriptions in the first quarter of product launch.
High Prescriber Productivity
Top 1,000 prescribers are filling over 40% more scripts per doctor than a comparable point in the competing VUITY launch, and >55% of prescribing doctors have written VIZZ multiple times, indicating strong productivity and repeat prescribing among early adopters.
Strong Physician Awareness and Enrollment
Aided awareness among ECPs is ~98% and unaided awareness ~79%; the company has enrolled more than 14,000 ECP locations in its program and is already seeing adoption among doctors who never wrote VUITY.
Expanding Field Footprint
Field organization expanding from 88 to 117 reps (adding 29 reps) to increase reach and frequency; outside field reach expected to cover ~15,000 ECPs.
Direct-to-Consumer (DTC) Early Momentum
DTC campaign launched mid-January; website traffic running ~5x baseline with spikes up to 10x during national activations; YouTube brand lift performing ~2x above benchmark and click-through/cost-per-impression metrics exceeding relevant benchmarks.
Financial Strength / Cash Position
Company ended FY2025 with approximately $292.3 million in cash, cash equivalents and marketable securities and remains debt-free, providing runway to invest behind launch and category building.
Favorable Revenue Per Unit Metrics
Reported blended gross-to-net ratio of ~90% (~$67 per monthly package) and an expected net cash per unit of ~$60 per monthly package, consistent with company expectations.
Global Regulatory Progress
Five ex-U.S. NDA/equivalent submissions completed (China NDA review underway; submissions in South Korea, Thailand and Singapore; EMA submission submitted; MHRA to follow); company anticipates >10 ex-U.S. submissions by year-end with potential approvals in 2027.
Low Near-Term R&D Spend
R&D expense fell to $0 in Q4 2025 (from $5.9M YoY), reflecting conclusion of Phase III CLARITY and approval—reducing near-term investment needs on the P&L.
LENZ Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
LENZ Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Mar 25, 2026 | $9.03 | $9.07 | +0.44% |
Nov 05, 2025 | $28.05 | $21.47 | -23.46% |
Jul 30, 2025 | $31.67 | $30.76 | -2.87% |
May 07, 2025 | $25.34 | $25.87 | +2.09% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Lenz Therapeutics, Inc. (LENZ) report earnings?
Lenz Therapeutics, Inc. (LENZ) is schdueled to report earning on May 13, 2026, After Close (Confirmed).
What is Lenz Therapeutics, Inc. (LENZ) earnings time?
Lenz Therapeutics, Inc. (LENZ) earnings time is at May 13, 2026, After Close (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is LENZ EPS forecast?
LENZ EPS forecast for the fiscal quarter 2026 (Q1) is -1.01.